To determine the prevalence of macrolide antibiotic and levofloxacin resistance in infections with Streptococcus pyogenes (group A streptococcus or GAS), strains were collected from 45 medical institutions in various parts of Japan between October 2003 and September 2006. Four hundred and eighty-two strains from patients with GAS infections were characterized genetically. Strains were classified into four groups according to the type of infection: invasive infections (n=74) including sepsis, cellulitis and toxic-shock-like syndrome; acute otitis media (AOM; n=23); abscess (n=53); and pharyngotonsillitis (n=332). Among all strains, 32 emm types were identified; emm1 was significantly more common in invasive infections (39.2 %) and AOM (43.5 %) than in abscesses (3.8 %) or pharyngotonsillitis (10.2 %). emm12 and emm4 each accounted for 23.5 % of pharyngotonsillitis cases. Susceptibility of GAS strains to eight β-lactam agents was excellent, with MICs of 0.0005–0.063 μg ml−1. Macrolide-resistant strains accounted for 16.2 % of all strains, while the percentages of strains possessing the resistance genes erm(A), erm(B) and mef(A) were 2.5 %, 6.2 % and 7.5 %, respectively. Although no strains with high resistance to levofloxacin were found, strains with an MIC of 2–4 μg ml−1 (17.4 %) had amino acid substitutions at either Ser-79 or Asp-83 in ParC. These levofloxacin-intermediately resistant strains included 16 emm types, but macrolide-resistant strains were more likely than others to represent certain emm types.
BeallB.,
FacklamR.,
ThompsonT.1996; Sequencing emm -specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 34:953–958
FujitaT.,
KawaguchiT.,
FujiiY.2007; The closeout report: database construction of oral antimicrobial agents using the results from drug use investigations. Jpn J Antibiot 60:265–307 (in Japanese [CrossRef]
KimuraK.,
SuzukiS.,
WachinoJ. I.,
KurokawaH.,
YamaneK.,
ShibataN.,
NaganoN.,
KatoH.,
ShibayamaK.,
ArakawaY.2008; First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 52:2890–2897[CrossRef]
OrschelnR. C.,
JohnsonD. R.,
OlsonS. M.,
PrestiR. M.,
MartinJ. M.,
KaplanE. L.,
StorchG. A.2005; Intrinsic reduced susceptibility of serotype 6 Streptococcus pyogenes to fluoroquinolone antibiotics. J Infect Dis 191:1272–1279[CrossRef]
ReinertR. R.,
LuttickenR.,
Al-LahhamA.2004; High-level fluoroquinolone resistance in a clinical Streptococcus pyogenes isolate in Germany. Clin Microbiol Infect 10:659–662[CrossRef]
RogersS.,
CommonsR.,
DanchinM. H.,
SelvarajG.,
KelpieL.,
CurtisN.,
Robins-BrowneR.,
CarapetisJ. R.2007; Strain prevalence, rather than innate virulence potential, is the major factor responsible for an increase in serious group A streptococcus infections. J Infect Dis 195:1625–1633[CrossRef]
RuoffK. L.,
WhileyR. A.,
BeightonD.2003; Streptococcus
. In Manual of Clinical Microbiology pp. 405–421 Edited by P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller & R. H. Yolken. Washington, DC: American Society for Microbiology.
StevensD. L.,
TannerM. H.,
WinshipJ.,
SwartsR.,
RiesK. M.,
SchlievertP. M.,
KaplanE.1989; Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 321:1–7[CrossRef]
SunaoshiK.,
NakayamaE.,
KobayashiR.,
SuzukiE.,
TajimaT.,
UbukataK.2004; Antibiotic susceptibility and T type identification of Streptococcus pyogenes isolated from pediatric outpatients with pharingotonsillitis. Jpn J Chemother 52:401–407
TewodrosW.,
KronvallG.2005; M protein gene ( emm type) analysis of group A beta-hemolytic streptococci from Ethiopia reveals unique patterns. J Clin Microbiol 43:4369–4376[CrossRef]
UbukataK.,
AsahiY.,
YamaneA.,
KonnoM.1996; Combinational detection of autolysin and penicillin-binding protein 2B genes of Streptococcus pneumoniae by PCR. J Clin Microbiol 34:592–596
YanS. S.,
FoxM. L.,
HollandS. M.,
StockF.,
GillV. J.,
FedorkoD. P.2000; Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes : identification of gyrA and parC and specification of point mutations associated with resistance. Antimicrob Agents Chemother 44:3196–3198[CrossRef]